

FORM PTO-1449/A and B (modified PTO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/649,584

ATTY. DOCKET NO.: C1039.70084US00

FILING DATE: August 25, 2003

CONFIRMATION NO.: 5262

APPLICANT: Krieg et al.

GROUP ART UNIT: 1633

EXAMINER: Maria Marvich

Sheet 1 of 14

U.S. PATENT DOCUMENTS

Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/M.M./	A1	5,567,604		Rando et al.	10-22-1996
	A2	5,594,122		Friesen	01-14-1997
	A3	5,663,153		Hutcherson et al.	09-02-1997
	A4	5,684,147		Agrawal et al.	11-04-1997
	A5	5,723,335		Hutcherson et al.	03-03-1998
	A6	5,723,335		Hutcherson et al.	03-03-1998
	A7	6,107,062		Hu et al.	08-22-2000
	A8	6,114,167		Symonds et al.	09-05-2000
	A9	6,194,388	B1	Krieg et al.	02-27-2001
	A10	6,207,646	B1	Krieg et al.	03-27-2001
	A11	6,214,806	B1	Krieg et al.	04-10-2001
	A12	6,218,371	B1	Krieg et al.	04-17-2001
	A13	6,221,882	B1	Macfarlane	04-24-2001
	A14	6,239,116	B1	Krieg et al.	05-29-2001
	A15	6,339,068	B1	Krieg et al.	01-15-2002
	A16	6,399,630	B1	Macfarlane	06-04-2002
	A17	6,406,705	B1	Davis et al.	06-18-2002
	A18	6,429,199	B1	Krieg et al.	08-06-2002
	A19	6,479,504	B1	Macfarlane et al.	11-12-2002
	A20	6,498,147	B1	Nerenberg et al.	12-24-2002
	A21	6,514,948	B1	Raz et al.	02-04-2003
	A22	6,521,637	B2	Macfarlane	02-18-2003
	A23	6,534,062	B1	Raz et al.	03-18-2003
	A24	6,589,940	B1	Raz et al.	07-08-2003
	A25	6,610,661	B1	Carson et al.	08-26-2003
	A26	6,653,292	B1	Krieg et al.	11-25-2003
	A27	6,727,230	B1	Hutcherson et al.	04-27-2004
	A28	6,737,066	B1	Moss	05-18-2004
	A29	6,821,957	B1	Krieg et al.	11-23-2004
	A30	6,849,725	B2	Junghans et al.	02-01-2005
	A31	6,943,240	B2	Bauer et al.	09-13-2005
	A32	6,949,520	B1	Hartmann et al.	09-27-2005
/M.M./	A33	7,001,890	B1	Wagner et al.	02-21-2006

EXAMINER:

/Maria Marvich/

DATE CONSIDERED:

11/19/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584		ATTY. DOCKET NO.: C1039.70084US00	
				FILING DATE: August 25, 2003		CONFIRMATION NO.: 5262	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1633		EXAMINER: Maria Marvich	
Sheet	2	of	14				

/M.M./	A34	7,223,741	B2	Krieg	05-29-2007
	A35	7,271,156	B2	Krieg et al.	07-18-2007
	A36	2001-0044416	A1	McCluskie et al.	11-22-2001
	A37	2002-0028784	A1	Van Nest et al.	03-07-2002
	A38	2002-0086839	A1	Raz et al.	07-04-2002
	A39	2002-0091097	A1	Bratzler et al.	07-11-2002
	A40	2002-0142977	A1	Raz et al.	10-03-2002
	A41	2002-0156033	A1	Bratzler et al.	10-24-2002
	A42	2002-0164341	A1	Davis et al.	11-07-2002
	A43	2002-0165178	A1	Schetter et al.	11-07-2002
	A44	2002-0198165	A1	Bratzler et al.	12-26-2002
	A45	2003-0026782	A1	Krieg	02-02-2003
	A46	2003-0026801	A1	Weiner et al.	02-06-2003
	A47	2003-0050263	A1	Krieg et al.	03-13-2003
	A48	2003-0050268	A1	Krieg et al.	03-13-2003
	A49	2003-0055014	A1	Bratzler	03-20-2003
	A50	2003-0091599	A1	Davis et al.	05-15-2003
	A51	2003-0100527	A1	Krieg et al.	05-29-2003
	A52	2003-0119773	A1	Raz et al.	06-26-2003
	A53	2003-0139364	A1	Krieg et al.	07-24-2003
	A54	2003-0143213	A1	Raz et al.	07-31-2003
	A55	2003-0147870	A1	Raz et al.	08-07-2003
	A56	2003-0148316	A1	Lipford et al.	08-07-2003
	A57	2003-0148976	A1	Krieg et al.	08-07-2003
	A58	2003-0166001	A1	Lipford	09-04-2003
	A59	2003-0181406	A1	Schetter et al.	09-25-2003
	A60	2003-0191079	A1	Krieg et al.	10-09-2003
	A61	2003-0224010	A1	Davis et al.	12-04-2003
	A62	2003-0232074	A1	Lipford et al.	12-18-2003
	A63	2003-0232780	A1	Carson et al.	12-18-2003
	A64	2003-0232856	A1	Macfarlane	12-18-2003
	A65	2004-0006010	A1	Carson et al.	01-08-2004
	A66	2004-0006034	A1	Raz et al.	01-08-2004
	A67	2004-0009949	A1	Krieg	01-15-2004
	A68	2004-0030118	A1	Wagner et al.	02-12-2004
	A69	2004-0053880	A1	Krieg	03-18-2004
/M.M./	A70	2004-0067902	A9	Bratzler et al.	04-08-2004

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/19/2008
------------------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584		ATTY. DOCKET NO.: C1039.70084US00	
				FILING DATE: August 25, 2003		CONFIRMATION NO.: 5262	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1633		EXAMINER: Maria Marvich	
Sheet	3	of	14				

/M.M./	A71	2004-0067905	A1	Krieg	04-08-2004
	A72	2004-0087534	A1	Krieg et al.	05-06-2004
	A73	2004-0087538	A1	Krieg et al.	05-06-2004
	A74	2004-0092472	A1	Krieg	05-13-2004
	A75	2004-0105872	A1	Klinman et al.	06-03-2004
	A76	2004-0106568	A1	Krieg et al.	06-03-2004
	A77	2004-0131628	A1	Bratzler et al.	07-08-2004
	A78	2004-0132685	A1	Krieg et al.	07-08-2004
	A79	2004-0142469	A1	Krieg et al.	07-22-2004
	A80	2004-0143112	A1	Krieg et al.	07-22-2004
	A81	2004-0147468	A1	Krieg et al.	07-29-2004
	A82	2004-0152649	A1	Krieg	08-05-2004
	A83	2004-0152656	A1	Krieg et al.	08-05-2004
	A84	2004-0152657	A1	Krieg et al.	08-05-2004
	A85	2004-0162258	A1	Krieg et al.	08-19-2004
	A86	2004-0162262	A1	Krieg et al.	08-19-2004
	A87	2004-0167089	A1	Krieg et al.	08-26-2004
	A88	2004-0171150	A1	Krieg et al.	09-02-2004
	A89	2004-0171571	A1	Krieg et al.	09-02-2004
	A90	2004-0181045	A1	Krieg et al.	09-16-2004
	A91	2004-0198680	A1	Krieg	10-07-2004
	A92	2004-0198688	A1	Krieg et al.	10-07-2004
	A93	2004-0229835	A1	Krieg et al.	11-18-2004
	A94	2004-0234512	A1	Wagner et al.	11-25-2004
	A95	2004-0235770	A1	Davis et al.	11-25-2004
	A96	2004-0235774	A1	Bratzler et al.	11-25-2004
	A97	2004-0235777	A1	Wagner et al.	11-25-2004
	A98	2004-0235778	A1	Wagner et al.	11-25-2004
	A99	2004-0266719	A1	McCluskie et al.	12-30-2004
	A100	2005-0004061	A1	Krieg et al.	01-06-2005
	A101	2005-0004062	A1	Krieg et al.	01-06-2005
	A102	2005-0009774	A1	Krieg et al.	01-13-2005
	A103	2005-0032734	A1	Davis et al.	02-10-2005
	A104	2005-0032736	A1	Krieg et al.	02-10-2005
	A105	2005-0037403	A1	Krieg et al.	02-17-2005
	A106	2005-0037985	A1	Krieg et al.	02-17-2005
/M.M./	A107	2005-0043529	A1	Davis et al.	02-24-2005

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/19/2008
----------------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584		ATTY. DOCKET NO.: C1039.70084US00	
				FILING DATE: August 25, 2003		CONFIRMATION NO.: 5262	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1633		EXAMINER: Maria Marvich	
Sheet	4	of	14				

/M.M./	A108	2005-0049215	A1	Krieg et al.	03-03-2005
	A109	2005-0049216	A1	Krieg et al.	03-03-2005
	A110	2005-0054601	A1	Wagner et al.	03-10-2005
	A111	2005-0054602	A1	Krieg et al.	03-10-2005
	A112	2005-0059626	A1	Van Nest et al.	03-17-2005
	A113	2005-0059619	A1	Krieg et al.	03-17-2005
	A114	2005-0059625	A1	Krieg et al.	03-17-2005
	A115	2005-0070491	A1	Krieg et al.	03-31-2005
	A116	2005-0075302	A1	Hutcherson et al.	04-07-2005
	A117	2005-0100983	A1	Bauer et al.	05-12-2005
	A118	2005-0101554	A1	Krieg et al.	05-12-2005
	A119	2005-0101557	A1	Krieg et al.	05-12-2005
	A120	2005-0119273	A1	Lipford et al.	06-02-2005
	A121	2005-0123523	A1	Krieg et al.	06-09-2005
	A122	2005-0130911	A1	Uhlmann et al.	06-16-2005
	A123	2005-0148537	A1	Krieg et al.	07-07-2005
	A124	2005-0169888	A1	Hartman et al.	08-04-2005
	A125	2005-0171047	A1	Krieg et al.	08-04-2005
	A126	2005-0181422	A1	Bauer et al.	08-18-2005
	A127	2005-0182017	A1	Krieg	08-18-2005
	A128	2005-0197314	A1	Krieg et al.	09-08-2005
	A129	2005-0215501	A1	Lipford et al.	09-29-2005
	A130	2005-0233995	A1	Krieg et al.	10-20-2005
	A131	2005-0233999	A1	Krieg et al.	10-20-2005
	A132	2005-0239732	A1	Krieg et al.	10-27-2005
	A133	2005-0239733	A1	Jurk et al.	10-27-2005
	A134	2005-0239734	A1	Uhlmann et al.	10-27-2005
	A135	2005-0239736	A1	Krieg et al.	10-27-2005
	A136	2005-0244379	A1	Krieg et al.	11-03-2005
	A137	2005-0244380	A1	Krieg et al.	11-03-2005
	A138	2005-0245477	A1	Krieg et al.	11-03-2005
	A139	2005-0250726	A1	Krieg et al.	11-10-2005
	A140	2005-0256073	A1	Lipford et al.	11-17-2005
	A141	2005-0266015	A1	Clerici et al.	12-01-2005
	A142	2005-0267064	A1	Krieg et al.	12-01-2005
	A143	2005-0277604	A1	Krieg et al.	12-15-2005
/M.M./	A144	2005-0277609	A1	Krieg et al.	12-15-2005

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/19/2008
---------------------------	-----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584		ATTY. DOCKET NO.: C1039.70084US00	
				FILING DATE: August 25, 2003		CONFIRMATION NO.: 5262	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1633		EXAMINER: Maria Marvich	
Sheet	5	of	14				

/M.M./	A145	2006-0003955	A1	Krieg et al.	01-05-2006
	A146	2006-0003962	A1	Ahluwalia et al.	01-05-2006
	A147	2006-0019916	A1	Krieg et al.	01-26-2006
	A148	2006-0019923	A1	Davis et al.	01-26-2006
	A149	2006-0058251	A1	Krieg et al.	03-16-2006
	A150	2006-0089326	A1	Krieg et al.	04-27-2006
	A151	2006-0094683	A1	Krieg et al.	05-04-2006
	A152	2006-0140875	A1	Krieg et al.	06-29-2006
	A153	2006-0154890	A1	Bratzler et al.	07-13-2006
	A154	2006-0172966	A1	Lipford et al.	08-03-2006
	A155	2006-0188913	A1	Krieg et al.	08-24-2006
	A156	2006-0211639	A1	Bratzler et al.	09-21-2006
	A157	2006-0211644	A1	Krieg et al.	09-21-2006
	A158	2006-0229271	A1	Krieg et al.	10-12-2006
	A159	2006-0241076	A1	Uhlmann et al.	10-26-2006
	A160	2006-0246035	A1	Ahluwalia et al.	11-02-2006
	A161	2006-0286070	A1	Hartmann et al.	12-21-2006
	A162	2006-0287263	A1	Davis et al.	12-21-2006
	A163	2007-0009482	A1	Krieg et al.	01-11-2007
	A164	2007-0010470	A1	Krieg et al.	01-11-2007
	A165	2007-0037767	A1	Bratzler et al.	02-15-2007
	A166	2007-0065467	A1	Krieg et al.	03-22-2007
	A167	2007-0066553	A1	Krieg et al.	03-22-2007
	A168	2007-0066554	A1	Krieg et al.	03-22-2007
	A169	2007-0078104	A1	Krieg et al.	04-05-2007
	A170	2007-0129320	A9	Davis et al.	06-07-2007
	A171	2007-0142315	A1	Forsbach et al.	06-21-2007
	A172	2007-0184465	A1	Wagner et al.	08-09-2007
	A173	2007-0202128	A1	Krieg et al.	08-30-2007
	A174	2007-0224210	A1	Krieg et al.	09-27-2007
/M.M./	A175	2007-0232622	A1	Lipford et al.	10-04-2007

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/19/2008
------------------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584	ATTY. DOCKET NO.: C1039.70084US00
				FILING DATE: August 25, 2003	CONFIRMATION NO.: 5262
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Maria Marvich
Sheet	6	of	14		

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B1	EP	0 302 758	A1	New England Medical Center Hospitals,	02-08-1989	
	B2	EP	0 468 520	A2	Mitsui Toatsu Chemicals, Inc.	01-29-1992	
	B3	WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999	
	B4	WO	00/06588	A1	University of Iowa Research Foundation	02-10-2000	
	B5	WO	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000	
	B6	WO	00/21556	A1	Dynavax Technologies Corporation	04-20-2000	
	B7	WO	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000	
	B8	WO	01/00232	A2	SmithKline Beecham Biologicals, S.A.	01-04-2001	
	B9	WO	01/54719	A2	SmithKline Beecham Biologicals, S.A.	08-02-2001	
	B10	WO	2004/007743	A2	Coley Pharmaceutical GMBH	01-22-2004	
	B11	WO	2004/026888	A2	Coley Pharmaceutical GMBH	04-01-2004	
	B12	WO	2004/094671	A2	Coley Pharmaceutical GMBH	11-04-2004	
	B13	WO	2006/080946	A2	Coley Pharmaceutical GMBH	08-03-2006	
	B14	WO	2007/031877	A2	Coley Pharmaceutical GMBH	03-22-2007	
	B15	WO	2007/038720	A2	Coley Pharmaceutical GMBH	04-05-2007	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	Press Release, January 2007, "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy".	
	C2	Press Release, June 2007, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer".	
	C3	AGRAWAL et al., Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 2002 Mar;8(3):114-21.	
	C4	AGRAWAL et al., Was induction of HIV-1 through TLR9? J Immunol. 2003 Aug;15;171(4):1621.	
	C5	ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8.	
	C6	BRANDA et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol. 1993 May 25;45(10):2037-43.	
	C7	BRANDA et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J Lab Clin Med. 1996 Sep;128(3):329-38.	
	C8	BRANDA et al., B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol. 1996 May;79(2):115-21.	

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/19/2008
----------------------------------	------------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584	ATTY. DOCKET NO.: C1039.70084US00
				FILING DATE: August 25, 2003	CONFIRMATION NO.: 5262
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Maria Marvich
Sheet	7	of	14		

C9	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93.	
C10	CHU et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997 Nov 17;186(10):1623-31.	
C11	COWDERY et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol. 1996 Jun 15;156(12):4570-5.	
C12	DEML et al., Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins. Clin Chem Lab Med. 1999 Mar;37(3):199-204.	
C13	EQUUS et al., Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J Immunol. 2003 May 15;170(10):5159-64.	
C14	FIELDS et al., Fields' Virology. 2001;1:1153.	
C15	HALPERN et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol. 1996 Jan 10;167(1):72-8.	
C16	HASLETT et al., Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J Infect Dis. 2000 Apr;181(4):1264-72.	
C17	HAVLIR et al., Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med. 1998 Oct 29;339(18):1261-8.	
C18	HO, Toward HIV eradication or remission: the tasks ahead. Science. 1998 Jun 19;280(5371):1866-7.	
C19	IMAMI et al., Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 1999 Nov 20;15(17):1499-508.	
C20	IVERSEN et al., Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res Dev. 1994 Spring;4(1):43-52.	
C21	KATAOKA et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG. Jpn J Cancer Res. 1992 Mar;83(3):244-7.	
C22	KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. Jpn J Med Sci Biol. 1990 Oct;43(5):171-82.	
C23	KIMURA et al., Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. J Biochem (Tokyo). 1994 Nov;116(5):991-4.	
C24	KLINMAN et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83.	
C25	KNIFE et al., eds., Fields' Virology. 2001;1:1004-16.	
C26	KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58 th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
C27	KRIEG et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 1996 Summer;6(2):133-9.	

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/20/2008
------------------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584	ATTY. DOCKET NO.: C1039.70084US00
				FILING DATE: August 25, 2003	CONFIRMATION NO.: 5262
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Maria Marvich
Sheet	8	of	14		

	C28	KRIEG et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev. 1995 Winter;5(4):241.	
	C29	KRIEG, CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol. 1995 Nov;15(6):284-92.	
	C30	KRIEG et al., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546-9.	
	C31	KRIEG, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med. 1996 Aug;128(2):128-33.	
	C32	KRIEG et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J Immunol. 1989 Oct 15;143(8):2448-51.	
	C33	KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996:116.	
	C34	KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.	
	C35	KRIEG et al., Infection. 1996: McGraw Hill Book. 1996:242-3.	
	C36	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
	C37	KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec;27(6):460-71.	
	C38	KRIEG, Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84.	
	C39	KULKARNI et al., Effect of dietary nucleotides on response to bacterial infections. JPEN J Parenter Enteral Nutr. 1986 Mar-Apr;10(2):169-71.	
	C40	KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8.	
	C41	KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992 Jul;14(5):773-82.	
	C42	KURAMOTO et al., Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res. 1992 Nov;83(11):1128-31.	
	C43	KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. Microbiol Immunol. 1989;33(11):929-40.	
	C44	LEDERMAN et al., Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation. Antisense Nucleic Acid Drug Dev. 1996 Winter;6(4):281-9.	
	C45	LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997 Sep;27(9):2340-4.	
	C46	LIPFORD et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol. 1997 Dec;27(12):3420-6.	

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/20/2008
------------------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584	ATTY. DOCKET NO.: C1039.70084US00
				FILING DATE: August 25, 2003	CONFIRMATION NO.: 5262
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Maria Marvich
Sheet	9	of	14		

	C47	LIU et al., Recombinant interleukin-6 protects mice against experimental bacterial infection. Infect Immun. 1992 Oct;60(10):4402-6.	
	C48	MANCILLA-RAMIREZ et al., [Phosphatidylcholine induces an increase in the production of interleukin-6 and improves survival of rats with neonatal sepsis caused by Klebsiella pneumoniae] Gac Med Mex. 1995 Jan-Feb;131(1):14-22. Spanish.	Y – Abstract
	C49	MATSUKURA et al., Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4244-8.	
	C50	MESSINA et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Cell Immunol. 1993 Mar;147(1):148-57.	
	C51	MOJCIK et al., Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. Clin Immunol Immunopathol. 1993 May;67(2):130-6.	
	C52	MOSS et al., In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides. Vaccine. 2000 Jan 6;18(11-12):1081-7.	
	C53	PISETSKY et al., The immunologic properties of DNA. J Immunol. 1996 Jan 15;156(2):421-3.	
	C54	PISETSKY et al., Immunological properties of bacterial DNA. Ann N Y Acad Sci. 1995 Nov 27;772:152-63.	
	C55	PISETSKY et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 1994;54(2):101-7.	
	C56	PISETSKY, Immunologic consequences of nucleic acid therapy. Antisense Res Dev. 1995 Fall;5(3):219-25.	
	C57	PISETSKY et al., Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. Mol Biol Rep. 1993 Oct;18(3):217-21.	
	C58	RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40.	
	C59	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract 615.	
	C60	SATOH et al., Morphological and immunohistochemical characteristics of the heterogeneous prostate-like glands (paraurethral gland) seen in female Brown-Norway rats. Toxicol Pathol. 2001 Mar-Apr;29(2):237-41.	
	C61	SCHLAEPFER et al., CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J Virol. 2004 Nov;78(22):12344-54.	
	C62	SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J Interferon Cytokine Res. 1996 Oct;16(10):799-803.	
	C63	STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67-9.	
	C64	STEIN et al., Non-antisense effects of oligodeoxynucleotides. Antisense Technology. 1997; ch11: 241-64.	
	C65	STEIN et al., Antisense oligonucleotides as therapeutic agents—is the bullet really magical? Science. 1993 Aug 20;261(5124):1004-12.	

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/20/2008
---------------------------	-----------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584	ATTY. DOCKET NO.: C1039.70084US00
				FILING DATE: August 25, 2003	CONFIRMATION NO.: 5262
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Maria Marvich
Sheet	10	of	14		

	C66	TOKUNAGA et al., A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. Jpn J Cancer Res. 1988 Jun;79(6):682-6.	
	C67	TOKUNAGA et al., Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol. 1992;36(1):55-66.	
	C68	VERTHELYI et al., CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS. 2004 Apr 30;18(7):1003-8.	
	C69	WAAG et al., Injection of inactivated phase I Coxiella burnetii increases non-specific resistance to infection and stimulates lymphokine production in mice. Ann N Y Acad Sci. 1990;590:203-14.	
	C70	YAMAMOTO et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. Microbiol Immunol. 1994;38(10):831-6.	
	C71	YAMAMOTO et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol. 1992 Jun 15;148(12):4072-6.	
	C72	YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG] Kekkaku. 1994 Sep;69(9):571-4. Japanese.	Y-Abstract
	C73	YAMAMOTO et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev. 1994 Summer;4(2):119-22.	
	C74	YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res. 1994 Aug;85(8):775-9.	
	C75	YI et al., Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol. 1996 Dec 15;157(12):5394-402.	
	C76	YI et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol. 1996 Jan 15;156(2):558-64.	
	C77	Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for judgment based on failure to comply with 35 U.S.C. 135(b)). (Electronically filed, unsigned). June 7, 2004.	
	C78	Patent Interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in fact). (Electronically filed, unsigned). June 7, 2004.	
	C79	Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of enablement). (Electronically filed, unsigned). June 7, 2004.	
	C80	Patent Interference No. 105,171. Iowa Preliminary Motion 6 (for judgment based on lack of adequate written description). (Electronically filed, unsigned). June 7, 2004.	
	C81	Patent Interference No. 105,171. Iowa Preliminary Motion 7 (motion to redefine interference to designate claims as not corresponding to the Count). (Electronically filed, unsigned). June 7, 2004.	
	C82	Patent Interference No. 105,171. Iowa Preliminary Motion 8 (contingent motion to redefine the Count). (Electronically filed, unsigned). June 7, 2004.	
	C83	Patent Interference No. 105,171. Iowa Preliminary Motion 9 (motion for benefit of earlier application). (Electronically filed, unsigned). June 7, 2004.	

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/20/2008
------------------------------	--------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584	ATTY. DOCKET NO.: C1039.70084US00
				FILING DATE: August 25, 2003	CONFIRMATION NO.: 5262
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Maria Marvich
Sheet	11	of	14		

	C84	Patent Interference No. 105,171. Iowa Preliminary Motion 10 (contingent motion to redefine the interference by adding a continuation application). (Electronically filed, unsigned). July 2, 2004.	
	C85	Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.	
	C86	Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.	
	C87	Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.	
	C88	Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa Preliminary Motion 6 for judgment based on lack of adequate written description). September 9, 2004.	
	C89	Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa Preliminary Motion 7 to redefine the interference). September 9, 2004.	
	C90	Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa Preliminary Motion 8 to redefine the Count). September 9, 2004.	
	C91	Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa Contingent Motion 9 for benefit). September 9, 2004.	
	C92	Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa Contingent Motion 10 to redefine the interference). September 9, 2004.	
	C93	Patent Interference No. 105,171. Regents of the University of California Opposition 11 (to Iowa Contingent Motion 11 to suppress). October 15, 2004.	
	C94	Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.	
	C95	Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment of no interference in fact) (Electronically filed, unsigned). October 15, 2004.	
	C96	Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.	
	C97	Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for judgment based on lack of adequate written description) (Electronically filed, unsigned). October 15, 2004.	
	C98	Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
	C99	Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine the count) (Electronically filed, unsigned). October 15, 2004.	
	C100	Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
	C101	Patent Interference No. 105,171. Iowa Reply 11 (in support of Iowa Miscellaneous Motion to suppress). (Electronically filed, unsigned). October 18, 2004.	
	C102	Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004.	
	C103	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to designate additional claims of Iowa patent as corresponding to the Count). June 7, 2004.	
	C104	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for judgment based on lack of written description support and introducing new matter). June 7, 2004.	

EXAMINER:	/Maria Marvich/	DATE CONSIDERED:	11/20/2008
-----------	-----------------	------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584	ATTY. DOCKET NO.: C1039.70084US00
				FILING DATE: August 25, 2003	CONFIRMATION NO.: 5262
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Maria Marvich
Sheet	12	of	14		

	C105	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (for judgment based on anticipation). June 7, 2004.	
	C106	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (for judgment based on obviousness). June 7, 2004.	
	C107	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (for judgment based on anticipation). June 7, 2004.	
	C108	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (for judgment based on inequitable conduct). June 7, 2004.	
	C109	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 7 (for benefit of an earlier application under 37 CFR 1.633(j)). July 2, 2004.	
	C110	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.	
	C111	Amended Claims for Application Number 09/265,191, filed March 10, 1999.	
	C112	Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.	
	C113	Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004.	
	C114	Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
	C115	Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004.	
	C116	Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
	C117	Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004.	
	C118	Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004.	
	C119	Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633 (2) and (i)) (Electronically filed, unsigned). September 9, 2004.	
	C120	Patent Interference No. 105,171. Regents of the University of California Reply 1 (to Iowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004.	
	C121	Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.	
	C122	Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.	
	C123	Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.	
	C124	Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.	
	C125	Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.	

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/20/2008
---------------------------	-----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584	ATTY. DOCKET NO.: C1039.70084US00
				FILING DATE: August 25, 2003	CONFIRMATION NO.: 5262
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Maria Marvich
Sheet	13	of	14		

	C126	Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.	
	C127	Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.	
	C128	Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005.	
	C129	Patent Interference No. 105,171. Judgment and Order. March 10, 2005.	
	C130	Patent Interference No. 105,171. Regents of the University of California. Brief of Appellant. July 5, 2005.	
	C131	Patent Interference No. 105,171. University of Iowa and Coley Pharmaceutical Group, Inc. Brief of Appellees. August 17, 2005.	
	C132	Patent Interference No. 105,171. Regents of the University of California. Reply Brief of Appellant. September 6, 2005.	
	C133	Patent Interference No. 105,171. Regents of the University of California. Decision of CAFC. July 17, 2006.	
	C134	Patent Interference No. 105,526. Krieg Substantive Motion 1 (for unpatentability based on interference estoppel). (Electronically filed, unsigned).	
	C135	Patent Interference No. 105,526.. Krieg Substantive Motion 2 (for judgment based on inadequate written description and/or enablement). (Electronically filed, unsigned). June 18, 2007.	
	C136	Patent Interference No. 105,526. Krieg Contingent Responsive Motion (to add new claims 104 and 105). (Electronically filed, unsigned). July 25, 2007.	
	C137	Patent Interference No. 105,526. Krieg Substantive Motion 3 (for judgment based on prior art). (Electronically filed, unsigned). June 18, 2007.	
	C138	Patent Interference No. 105,526. Raz Motion 1 (Unpatentability of Krieg Claims under 35 U.S.C. § 112, First Paragraph). (Electronically filed, unsigned). June 18, 2007.	
	C139	Patent Interference No. 105,526. Raz Motion 2 (Raising a Threshold Issue of No Interference-in-Fact). (Electronically filed, unsigned). June 18, 2007.	
	C140	Patent Interference No. 105,526.. Raz Motion 3 (Krieg's Claims are Unpatentable Over Prior Art Under 35 U.S.C. § 102(b)) (Electronically filed, unsigned). June 18, 2007.	
	C141	Patent Interference No. 105,526. Raz Motion 4 (To Designate Krieg Claims 46 and 82-84 as Corresponding to Count 1). (Electronically filed, unsigned). June 18, 2007.	
	C142	Patent Interference No. 105,526. Raz Responsive Miscellaneous Motion 5 (To revive the Raz Parent Application) (Electronically filed, unsigned) July 25, 2007.	
	C143	Patent Interference No. 105,526. Raz Contingent Responsive Motion 6 (To Add a New Claim 58) (Electronically filed, unsigned) July 25, 2007.	
	C144	Patent Interference No. 105,526. Krieg Opposition 1 (Opposition to Motion for Lack of Enablement and Written Description) (Electronically filed, unsigned) September 10, 2007.	
	C145	Patent Interference No. 105,526. Krieg Opposition 2 (to Raz Motion 2) (Electronically filed, unsigned) September 10, 2007.	
	C146	Patent Interference No. 105,526. Krieg Opposition 3 (To Raz Motion 3) (Electronically filed, unsigned) September 10, 2007.	
	C147	Patent Interference No. 105,526. Krieg Opposition 4 (Opposition to Motion for Designating Claims 46 and 82-84 as Corresponding to the Court) (Electronically filed, unsigned) September 10, 2007.	
	C148	Patent Interference No. 105,526. Krieg Opposition 6 (Opposition to Raz Contingent Responsive Motion 6) (Electronically filed, unsigned) September 10, 2007.	

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/20/2008
---------------------------	-----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/649,584	ATTY. DOCKET NO.: C1039.70084US00
				FILING DATE: August 25, 2003	CONFIRMATION NO.: 5262
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Maria Marvich
Sheet	14	of	14		

	C149	Patent Interference No. 105,526. Raz Opposition 1 (Opposing Krieg Substantive Motion 1) (Electronically filed, unsigned) September 10, 2007.	
	C150	Patent Interference No. 105,526. Raz Opposition 2 (Opposing Krieg Substantive Motion 2) (Electronically filed, unsigned) September 10, 2007.	
	C151	Patent Interference No. 105,526. Raz Opposition 4 (Opposing Krieg Contingent Responsive Motion to Add New Claims 104 and 105) (Electronically filed, unsigned) September 10, 2007.	
	C152	Patent Interference No. 105,526. Krieg Reply 1 (Reply to Raz opposition 1) October 5, 2007	
	C153	Patent Interference No. 105,526. Krieg Reply 2 (Reply to Raz opposition 2) October 5, 2007	
	C154	Patent Interference No. 105,526. Krieg Reply 4 (Reply to Raz opposition 4) October 5, 2007	
	C155	Patent Interference No. 105,526. Raz Reply 1 (Reply to Krieg opposition 1) October 5, 2007	
	C156	Patent Interference No. 105,526. Raz Reply 2 (Reply to Krieg opposition 2) October 5, 2007	
	C157	Patent Interference No. 105,526. Raz Reply 3 (Reply to Krieg opposition 3) October 5, 2007	
	C158	Patent Interference No. 105,526. Raz Reply 4 (Reply to Krieg opposition 4) October 5, 2007	
	C159	Patent Interference No. 105,526. Raz Reply 6 (Reply to Krieg opposition 6) October 5, 2007	
	C160	Patent Interference No. 105,526. Krieg Miscellaneous Motion 5 (To exclude exhibits 2066, 2070, 2071, 2072, 2073, 2074, 2075, 2076 and 2078) October 9, 2007.	
	C161	Patent Interference No. 105,526. Raz Opposition 5 (Opposing Krieg Miscellaneous Motion 5) October 25, 2007.	
	C162	Patent Interference No. 105,526. Raz Miscellaneous Motion 7 (To exclude evidence) October 19, 2007.	
	C163	Patent Interference No. 105,526. Krieg Opposition 7 (To Raz Miscellaneous Motion 7) October 25, 2007.	
	C164	Patent Interference No. 105,526. Krieg Reply 5 (Reply to Raz opposition 5) October 30, 2007.	
	C165	Patent Interference No. 105,526. Raz Reply 7 (Reply to Krieg opposition 7) October 30, 2007.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /Maria Marvich/	DATE CONSIDERED: 11/20/2008
----------------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.